Hsbc Holdings PLC Purchases New Position in Bio-Techne Corp $TECH

Posted by Brenda Bartman on Aug 28th, 2026

Hsbc Holdings PLC acquired a new position in Bio-Techne Corp (NASDAQ:TECH – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 242,208 shares of the biotechnology company’s stock, valued at approximately $17,110,000. Hsbc Holdings PLC owned 0.15% of Bio-Techne at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Goldman Sachs Group Inc. lifted its stake in shares of Bio-Techne by 12.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock valued at $62,379,000 after purchasing an additional 113,634 shares during the period. Woodline Partners LP grew its stake in Bio-Techne by 40.0% in the first quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock worth $783,000 after purchasing an additional 3,814 shares during the period. EverSource Wealth Advisors LLC grew its stake in Bio-Techne by 506.3% in the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 562 shares during the period. First Trust Advisors LP raised its holdings in Bio-Techne by 1,085.7% in the second quarter. First Trust Advisors LP now owns 105,418 shares of the biotechnology company’s stock worth $5,424,000 after purchasing an additional 96,527 shares in the last quarter. Finally, Natixis raised its holdings in Bio-Techne by 82.6% in the second quarter. Natixis now owns 24,991 shares of the biotechnology company’s stock worth $1,286,000 after purchasing an additional 11,306 shares in the last quarter. 98.95% of the stock is owned by institutional investors.

Bio-Techne Stock Up 0.1%

Bio-Techne stock opened at $72.47 on Friday. Bio-Techne Corp has a 12 month low of $43.19 and a 12 month high of $72.62. The stock has a fifty day simple moving average of $70.57 and a two-hundred day simple moving average of $59.67. The company has a current ratio of 4.55, a quick ratio of 3.35 and a debt-to-equity ratio of 0.09. The firm has a market cap of $11.36 billion, a price-to-earnings ratio of 63.02, a PEG ratio of 8.62 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. Bio-Techne had a return on equity of 13.23% and a net margin of 14.97%.The firm had revenue of $321.19 million for the quarter, compared to the consensus estimate of $314.63 million. During the same period in the prior year, the company posted $0.53 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Equities analysts predict that Bio-Techne Corp will post 1.76 EPS for the current fiscal year.

Bio-Techne Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Monday, August 24th will be issued a dividend of $0.65 per share. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date of this dividend is Monday, August 24th. This is a boost from Bio-Techne’s previous quarterly dividend of $0.08. Bio-Techne’s payout ratio is 27.83%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on TECH shares. William Blair cut shares of Bio-Techne from an “outperform” rating to a “market perform” rating in a report on Thursday, June 25th. Royal Bank Of Canada downgraded Bio-Techne from an “outperform” rating to a “sector perform” rating and boosted their target price for the stock from $62.00 to $73.00 in a report on Thursday, July 9th. Piper Sandler began coverage on Bio-Techne in a research note on Thursday, June 11th. They issued a “neutral” rating and a $65.00 target price on the stock. Zacks Research upgraded Bio-Techne from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Leerink Partners set a $73.00 price target on Bio-Techne in a research report on Thursday, June 25th. Two analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. Based on data from MarketBeat, Bio-Techne has an average rating of “Hold” and a consensus price target of $68.92.

Read Our Latest Report on TECH

About Bio-Techne

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.